The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFrontier Ip Regulatory News (FIPP)

Share Price Information for Frontier Ip (FIPP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 41.50
Bid: 40.00
Ask: 43.00
Change: 0.50 (1.22%)
Spread: 3.00 (7.50%)
Open: 41.50
High: 41.50
Low: 41.50
Prev. Close: 41.00
FIPP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Board Appointment

16 Dec 2011 07:00

RNS Number : 1015U
Frontier IP Group plc
16 December 2011
 



 

 

 

 

FIPP

 

Frontier IP Group Plc

("Frontier IP" or the "Company")

 

Appointment of Non-Executive Director

 

Frontier IP, which specialises in the commercialisation of university intellectual property, is pleased to announce that it has appointed Andrew Richmond to the Board as a Non-executive Director. Andrew will replace Tim Cockroft, who is stepping down from his role as a Non-executive Director. These changes will take place with immediate effect.

 

Andrew, aged 45, has substantial experience of the healthcare, stockbroking and private equity industries. He is currently a Lay Member of the Court of the University of Dundee, one of Frontier IP's three university partners. He is also a Non-executive Director of NHS Tayside, Chairman of the Angus Community Health Partnership and Deputy Chairman of the Scottish Ambulance Service.

 

Between 2002 and 2005, Andrew was a Director of Covenant Healthcare Group, the independent hospital provider backed by Phoenix Equity Partners ("Phoenix"), helping to build the business up until its sale for a substantial profit in 2005 to private equity firm Electra (now known as Cognetas). He also worked as an adviser on healthcare for Phoenix from 2002 to 2003. Previously, Andrew was a number one rated Healthcare, Pharmaceuticals, Biotechnology and Smaller Companies Analyst, having worked on the buy side at Fleming Investment Management and the sell side at UBS Phillips & Drew and then at Collins Stewart.

 

Commenting on the appointment, Executive Chairman of Frontier IP, Neil Crabb said,

 

"We are delighted to welcome Andrew to the Board. Andrew's experience in the healthcare and private equity industries and close working relationship with the University of Dundee represent an excellent fit with Frontier IP's activities. Andrew has a breadth of experience in both private and public sectors and I am sure he will make a valuable contribution as we continue to grow.

 

In addition, I would like to thank Tim Cockroft for his contribution during an important time in the development of the Company."

 

Andrew Richmond said, "I am very pleased to be joining the Board of Frontier IP. My appointment comes at an exciting time for the Company and its rich stream of partner intellectual property. I look forward to working with my new colleagues to further the expansion and growth of the business."

 

Disclosures required pursuant to Rule 17 or paragraph (g) of Schedule 2 of the AIM Rules for Companies

 

Kevin Andrew Richmond currently holds the following directorships or partnerships:

 

Rushyglen Limited

Laverock Properties Limited

 

For further information please contact:

 

Frontier IP Group plc T: 0131 220 9491

Neil Crabb, Executive Chairman

 

Biddicks T: 020 3178 6378

Katie Tzouliadis/ Sophie McNulty

 

Arbuthnot Securities Limited T: 020 7012 2000

Tom Griffiths/Ed Groome

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOALLFEDFVLELIL
Date   Source Headline
7th May 202410:15 amRNSTVG to collaborate with The Pirbright Institute
2nd May 20247:00 amRNSFrontier IP announces stake in DiaGen
17th Apr 20241:59 pmRNSHolding(s) in Company
12th Apr 20247:00 amRNSAppointment of Chief Financial Officer
2nd Apr 202412:44 pmRNSHolding(s) in Company
14th Mar 20247:00 amRNSUnaudited Half Year Results
4th Mar 20241:40 pmRNSHolding(s) in Company
29th Feb 20243:12 pmRNSSale of shares in Exscientia
30th Jan 202411:45 amRNSHolding(s) in Company
22nd Jan 20247:00 amRNSOctopus invest in Alusid as part of equity funding
29th Dec 202312:00 pmRNSTotal Voting Rights
19th Dec 20234:46 pmRNSHolding(s) in Company
15th Dec 20236:12 pmRNSReplacement - Result of AGM and Directorate Change
15th Dec 20232:07 pmRNSResult of AGM and Directorate Change
13th Dec 20237:00 amRNSPortfolio news - The Vaccine Group
11th Dec 20237:00 amRNSHolding(s) in Company
30th Nov 20235:00 pmRNSTotal Voting Rights
30th Nov 20237:00 amRNSExercise of Options & Director/PDMR Shareholdings
28th Nov 20237:00 amRNSBoard Change
21st Nov 20237:00 amRNSPosting of Annual Report and Notice of AGM
9th Nov 20235:27 pmRNSHolding(s) in Company
3rd Nov 20237:05 amRNSGrant of options
1st Nov 20235:48 pmRNSExercise of Options & PDMR Shareholdings & TVR
31st Oct 20237:01 amRNSBoard changes
31st Oct 20237:00 amRNSFinal results for the year ended 30 June 2023
23rd Oct 20237:00 amRNSNew portfolio company Deakin Bio-Hybrid Materials
12th Oct 20232:05 pmRNSHolding(s) in Company
21st Sep 20237:00 amRNSExscientia announces collaboration with Merck
14th Sep 20235:21 pmRNSHolding(s) in Company
14th Sep 20237:00 amRNSExercise of Options & Total Voting Rights
11th Sep 20237:00 amRNSPortfolio news – Pulsiv appoints Chairman and CPO
8th Sep 20237:00 amRNSExercise of Options & Total Voting Rights
10th Aug 20238:45 amRNSPortfolio news – Fieldwork Robotics
24th Jul 20237:00 amRNSPortfolio news – CamGraPhIC loan facility
20th Jul 20235:18 pmRNSHolding(s) in Company
1st Jun 20237:00 amRNSSale of shares in Exscientia
26th May 20236:06 pmRNSHolding(s) in Company
9th May 20237:00 amRNSTopps Tiles launches first Alusid made tile range
21st Apr 20234:00 pmRNSDirectorate Change
20th Apr 20235:26 pmRNSHolding(s) in Company
27th Mar 20235:17 pmRNSHolding(s) in Company
17th Mar 20232:46 pmRNSGrant of options
15th Mar 20237:00 amRNSBoard changes
15th Mar 20237:00 amRNSUnaudited Half Year Results
30th Jan 20237:00 amRNSAlusid in collaboration with Imerys
9th Jan 20237:00 amRNSCelerum appoints David Gladding as CEO
9th Dec 20224:08 pmRNSResult of AGM
7th Dec 20221:25 pmEQSThe Vaccine Group completes two deadly disease vaccination projects
6th Dec 20227:00 amRNSFrontier IP to host Portfolio Demo Day
5th Dec 20227:00 amRNSThe Vaccine Group completes Lassa fever project

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.